Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Reaffirmed as Buy by HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $38.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 165.18% from the company’s previous close.

A number of other research analysts have also recently issued reports on SNDX. Jefferies Financial Group reiterated a “buy” rating and issued a $35.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, September 29th. Bank of America reissued a “buy” rating on shares of Syndax Pharmaceuticals in a report on Wednesday, August 5th. JPMorgan Chase & Co. cut their target price on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings upgraded Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. Finally, UBS Group reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Thursday, October 1st. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.80.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX opened at $14.33 on Tuesday. The company has a debt-to-equity ratio of 38.95, a current ratio of 6.77 and a quick ratio of 6.44. Syndax Pharmaceuticals has a one year low of $12.99 and a one year high of $25.59. The company has a 50-day moving average of $18.98 and a two-hundred day moving average of $20.47. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -5.71 and a beta of 0.42.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.10). Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The business had revenue of $72.79 million during the quarter, compared to analyst estimates of $79.36 million. During the same period in the previous year, the firm posted ($0.83) EPS. The firm’s revenue for the quarter was up 91.8% on a year-over-year basis. On average, equities research analysts expect that Syndax Pharmaceuticals will post -2.03 earnings per share for the current year.

Institutional Trading of Syndax Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $197,177,000. Bank of America Corp DE bought a new position in Syndax Pharmaceuticals in the 2nd quarter worth approximately $88,426,000. Elmind Capital LP bought a new position in Syndax Pharmaceuticals in the 4th quarter worth approximately $38,974,000. Trails Edge Capital Partners LP bought a new position in Syndax Pharmaceuticals in the 2nd quarter worth approximately $24,264,600. Finally, Bank of New York Mellon Corp bought a new position in Syndax Pharmaceuticals in the 2nd quarter worth approximately $22,736,000.

Trending Headlines about Syndax Pharmaceuticals

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Axatilimab was well tolerated in the MAXPIRe trial, with a safety profile comparable to placebo and no new safety signals. The drug remains in multiple cGVHD trials, with results expected later this year and in early 2028. Syndax Announces Topline Results from MAXPIRe Phase 2 Trial
• Neutral Sentiment: The Phase 2 MAXPIRe study evaluated axatilimab in IPF, a progressive lung disease. Syndax reported topline results but did not provide evidence that the treatment improved the trial’s primary lung-function measure. Syndax Announces MAXPIRe Topline Results
• Negative Sentiment: MAXPIRe failed to meet its primary endpoint, the annualized rate of decline in forced vital capacity (FVC). Syndax is ending development of axatilimab in IPF, eliminating a potential indication and likely reducing the drug’s long-term revenue opportunity. Syndax MAXPIRe Trial Misses Primary Endpoint
• Negative Sentiment: The trial failure triggered a sharp selloff as investors reassessed Syndax’s pipeline value and became more dependent on the company’s cGVHD programs for future growth. The setback is particularly important because Syndax remains loss-making and has reported quarterly revenue below analyst expectations. Syndax IPF Trial Misses Endpoint

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research programs target biological pathways involved in malignancy and immune-related conditions, with an emphasis on medicines that may address significant unmet medical needs.

Syndax’s lead product, Revuforj (revumenib), is an oral menin inhibitor approved by the U.S. Food and Drug Administration for treating relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients aged one year and older.